Skip to main content

Table 1 Patient characteristics

From: Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy

 

Age (years)

Weight (kg)

Sex

Race

APACHE II

SOFA

Voriconazole indication

Mean ± SD

53 ± 11

81 ± 14

50% Male

70% White

32 ± 4

16 ± 4

Pulmonary aspergillosis (n = 4)

10% Asian

Empiric broad spectrum antifungal (n = 4)

Median (range)

55 (33–70)

83 (54–100)

 

10% Hispanic/White

31 (27–38)

17 (9–20)

Scedosporium brain abscess (n = 1)

10% Native American

Candida glabrata peritonitis (n = 1)

  1. Data are presented as mean ± standard deviation (SD); median (minimum to maximum range); or numbers/proportions. APACHE II, Acute Physiologic and Chronic Health Evaluation II score; SOFA, Sequential Organ Failure Assessment score.